SCHEMBL14779602

SCHEMBL14779602

CC(C)(C)[SiH2]OC(C)(C)[C@@H]1CCCN1Cc1cncc(Br)c1

nearest known ligand 0.37

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.37
CHRNA4 P43681 1/20 0.37
HSD17B10 Q99714 1/20 0.34
CASR P41180 1/20 0.31
TACR1 P25103 1/20 0.31
SLC6A4 P31645 1/20 0.31
KCNH2 Q12809 1/20 0.31
KDM4E B2RXH2 1/20 0.31
POLB P06746 1/20 0.31
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31259970 1.00 CHRNB2 (0.37) CHRNB2CHRNA4HSD17B10CASRTACR1
SCHEMBL14778972 0.79 HCRTR1 (0.35) HSD17B10
SCHEMBL14784306 0.79 HCRTR1 (0.35) HSD17B10
SCHEMBL14778198 0.78 CHRNB2 (0.39) CHRNB2CHRNA4HSD17B10ALDH1A1
SCHEMBL14779611 0.78 CHRNB2 (0.39) CHRNB2CHRNA4HSD17B10ALDH1A1
SCHEMBL14780229 0.74 CYP11B1 (0.51)
SCHEMBL14779140 0.72 HDAC8 (0.51) CHRNB2CHRNA4ALDH1A1
SCHEMBL14779137 0.72 HDAC8 (0.51) CHRNB2CHRNA4ALDH1A1
SCHEMBL14779601 0.71 CHRNB2 (0.44) CHRNB2CHRNA4HSD17B10
SCHEMBL14780346 0.70 CHRNB2 (0.42) CHRNB2CHRNA4TACR1SLC6A4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3653618-B1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2025-01-08 EP disclosed
EP-3653618-A1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2020-05-20 EP disclosed
EP-2755963-B1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2019-10-30 EP disclosed
US-9260408-B2 Dihydroquinoline-2-one derivatives HOFFMANN-LA ROCHE INC. (US) 2016-02-16 US disclosed
EP-2755963-A1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2014-07-23 EP disclosed
US-20130072679-A1 DIHYDROQUINOLINE-2-ONE DERIVATIVES CINCOR PHARMA, INC. 2013-03-21 US disclosed
WO-2013037779-A1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072679-A1 DIHYDROQUINOLINE-2-ONE DERIVATIVES CYP11B1, CYP11B2, HSD11B1 CHRNB2 1135/4885CHRNA4 2935/4885HSD17B10 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.